Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HYDROXY(OXO)(3-{[(2Z)-4-[3-(1H-1,2,4-triazol-1-ylmethyl)phenyl]pyrimidin-2(5H)-ylidene]amino}phenyl)ammonium is an experimental small molecule compound with the molecular formula C19H15N7O2 and a molecular weight of approximately 373.37 g/mol[2]. It contains a triazole moiety linked to a phenyl-pyrimidine core and is structurally characterized by the presence of hydroxy and oxo functional groups. The drug has not been approved for any indication in the US or elsewhere and does not have any known clinical trial activity beyond preclinical or early research phases[2]. Its mechanism of action and pharmacological targets are currently unknown; there is no evidence it has reached advanced development or clinical use[6][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on HYDROXY(OXO)(3-{[(2Z)-4-[3-(1H-1,2,4-TRIAZOL-1-YLMETHYL)PHENYL]PYRIMIDIN-2(5H)-YLIDENE]AMINO}PHENYL)AMMONIUM.